Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCI/bupropion HCI) Extended-Release Tablets, which is approved in the United States. Orexigen’s partner for North America, Takeda Pharmaceuticals, markets CONTRAVE in the United States.
Outside of North America, Orexigen's strategy for naltrexone HCI /bupropion HCI is to purMore >>
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.